-
Panic Disorder or Generalized Anxiety Disorder
- Start 0.25 orally twice daily
- Titrate: Increase by 0.125 to 0.25 every 3 days to typical target dose of 1 mg/day divided
- Maximum Daily Dose: 4 mg (1.5 mg/day in elderly)
- No evidence of benefit for total daily dose above 1 to 2 mg
- Akinetic or Myoclonic Seizures or Lennox-Gestaut Syndrome (type of Petit Mal Seizures)
- Start 0.5 mg orally three times daily
- May increase dose by 0.5 to 1 mg orally every 3 days as needed to typical 2 to 8 mg/day in divided doses
- Maximum: 20 mg/day
-
REM Sleep Behavior Disorder (Not FDA approved)
- Dose 1 to 2 mg orally at bedtime
- Dosing
-
Children (age <10 years or weight <30 kg)
- Akinetic or Myoclonic Seizures or Lennox-Gestaut Syndrome (type of Petit Mal Seizures)
- Start 0.01 to 0.03 mg/kg/day orally divided 2 to 3 times daily
- May increase dose by 0.25 to 0.5 mg orally every 3 days as needed
- Maximum: 0.1 to 0.2 mg/day divided 2 to 3 times daily
-
Valium = Clonazepam Dose x2.5
-
Phenobarbital = Clonazepam Dose x7.5
- Half Life: 20-48 hours (up to 60 hours)
- Therapeutic Range: 20 to 80 ng/ml
- Rapidly and completely absorbed PO
- Metabolized via CYP3A4 to inactive metabolites
- Pregnancy Category D (esp. avoid in first trimester)
- Avoid in Lactation
-
Schedule IV Controlled Substance
- Sedation
- Weight gain
- Impaired academic performance
- Social anxiety with School Refusal in children
- Worsening of attention in children with ADHD
-
Hypersalivation
- (2019) Med Lett Drugs Ther 61(1578): 121-6
- (2020) Presc Lett, Resource #361206, Appropriate Use of Benzodiazepines
- Olson (2020) Clinical Pharmacology, Medmaster Miami, p. 55
- Hamilton (2020) Tarascon Pocket Pharmacopoeia
loading